Aerosol Interferon-α1b Anti-RSV Efficacy and Safety in Mice and Monkeys

A research article detailing the antiviral efficacy, pharmacokinetics, and safety of aerosolized human interferon-α1b against respiratory syncytial virus. The study reports in vitro EC₅₀ values, dose-dependent viral titer reduction in mice, and systemic bioavailability and safety data from cynomolgus monkeys. The dataset, a 4.0 MB PDF file, was authored by Mingming Yang and shared under a CC-BY-4.0 license on figshare in April 2026.

Use Cases

• Reviewing preclinical evidence for aerosolized interferon therapy based on the described in vitro and animal model results.
• Analyzing pharmacokinetic parameters for lung-targeted drug delivery based on the reported systemic bioavailability data from monkeys.
• Comparing antiviral efficacy against ribavirin based on the described reduction in lung viral titers in the mouse model.

Strengths

• Includes specific quantitative results such as an in vitro EC₅₀ of 4.64 ng/mL and a systemic bioavailability of 3.33% in monkeys.
• Provides comparative efficacy data, noting a greater reduction in viral load compared to ribavirin under the tested conditions (p < 0.001).
• Reports detailed safety findings, including that repeated dosing was well tolerated with only minimal to mild, reversible lung inflammation.

Limitations

• The dataset is a single PDF document; the underlying raw numerical or tabular data is not provided as a separate, machine-readable file.
• Row count and column-level documentation are absent, limiting direct computational analysis without manual data extraction.
• Data is derived from controlled preclinical studies; its applicability to human clinical settings requires further investigation.

Provenance

Source

figshare

Collection Method

Experimental study involving in vitro assays, an RSV-infected mouse model, and pharmacokinetic/toxicology studies in cynomolgus monkeys.

Freshness

Last updated 2026-04-30 05:40:07; freshness should be verified.